Department of Pediatrics, Cincinnati Children's Hospital and College of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio; and
Department of Pediatrics, Cincinnati Children's Hospital and College of Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio; and.
Pediatrics. 2018 Jun;141(6). doi: 10.1542/peds.2017-2580.
To identify predictors of attention-deficit/hyperactivity disorder (ADHD) medication continuity, hypothesizing greater continuity among children with (1) greater child acceptance of treatment, (2) parent belief in longer time course for ADHD, (3) positive differential between parent-perceived need for and concerns about medication, and (4) greater parent-perceived alliance with their child's doctor.
We conducted a prospective longitudinal cohort of 89 children aged 6 to 10 years old newly treated for ADHD by 1 of 44 pediatricians in 11 practices. Parents completed validated surveys on their beliefs about ADHD and medicine. We audited charts and obtained pharmacy dispensing records. In our analyses, we examined the relationship between predictor variables (eg, sociodemographic and clinical characteristics, quality of care, and belief measures) and short-term (first 90 days after starting medication) and long-term (91-450 days) medication continuity as defined by the number of days covered with medication.
Children had a median of 81% of days covered over 0 to 90 days and 54% of days covered over 91 to 450 days after starting medicine. In the first 90 days, medication coverage related to child age, satisfaction with information about medicine, medication titration, symptom reduction, parent beliefs about control over symptoms, uncertainty about treating with medicine, and working alliance. Long-term medication continuity related to child acceptance of treatment and differential between parent-perceived need for and concerns about medication at 3 months, not baseline factors.
Adherence is a process that can change over time in response to experiences with treatment. Interventions are needed to promote productive interactions between pediatricians and families in support of continuity.
确定注意力缺陷/多动障碍(ADHD)药物治疗连续性的预测因素,假设以下因素与更高的药物治疗连续性相关:(1)患儿对治疗的接受程度更高;(2)家长对 ADHD 治疗时间进程的信念;(3)父母对药物的需求与担忧之间的正差异;(4)父母对孩子的医生的感知联盟更强。
我们对 89 名年龄在 6 至 10 岁之间的儿童进行了前瞻性纵向队列研究,这些儿童由 11 个实践中的 44 名儿科医生中的 1 名新诊断为 ADHD。父母完成了关于他们对 ADHD 和药物的信念的有效调查问卷。我们审查了图表并获得了药房配药记录。在我们的分析中,我们检查了预测变量(例如,社会人口统计学和临床特征、护理质量和信念衡量)与短期(开始服药后 90 天内)和长期(91-450 天)药物连续性之间的关系,定义为用药物覆盖的天数。
儿童在开始用药后 0 至 90 天内有中位数 81%的天数被覆盖,在 91 至 450 天内有中位数 54%的天数被覆盖。在最初的 90 天内,药物覆盖范围与儿童年龄、对药物信息的满意度、药物滴定、症状减轻、父母对控制症状的信念、对用药物治疗的不确定性以及工作联盟有关。长期药物连续性与 3 个月时患儿对治疗的接受程度以及父母对药物的需求与担忧之间的差异有关,而与基线因素无关。
依从性是一个随时间变化的过程,可以根据治疗经历而变化。需要采取干预措施,促进儿科医生和家庭之间的积极互动,以支持连续性。